ClinicalTrials.gg
CompletedNCT03097133Aspire IIUpdated Apr 29, 2025Results posted

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

A Phase 3 interventional study of Esketamine and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 61 sites in 12 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.

Enrollment
4th of 17
230 · median 147
Started
2017
with 2 others
Phase 3
7 of 17
2 open now
Registered
5th of 17
by date
Lead sponsor
7 of 17
Janssen Research & Development, LLC

Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 3, and was the 5th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing esketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.

Read the detailed description

If you or a loved one are having thoughts of suicide, please seek immediate medical help. Go to the emergency room or call the National Suicide Prevention Lifeline at 1-800-273-8255.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must meet (5th edition) (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Psychiatric Interview (MINI)
  • Participants must have current suicidal ideation with intent, confirmed by a "Yes" response to Question B3 [Think (even momentarily) about harming or of hurting or of injuring yourself: with at least some intent or awareness that you might die as a result; or think about suicide (ie, about killing yourself)?] AND Question B10 [Intend to act on thoughts of killing yourself?] obtained from the MINI
  • In the physician's opinion, acute psychiatric hospitalization is clinically warranted due to participant's imminent risk of suicide
  • Participant has a Montgomery Asberg Depression Rating Scale (MADRS) total score of greater than (>) 28 predose on Day 1
  • As part of standard of care treatment, participant agrees to be hospitalized voluntarily for a recommended period of 14 days after randomization (may be shorter or longer if clinically warranted in the investigator's opinion) and take prescribed non- antidepressant therapy(ies) for at least the duration of the double-blind treatment phase (Day 25)

Exclusion criteria

Exclusion Criteria:

  • Participant has a current diagnosis of bipolar (or related disorders), antisocial personality disorder, or obsessive compulsive disorder
  • Participant currently meets DSM-5 criteria for borderline personality disorder. Note: Participant not meeting full DSM-5 criteria for borderline personality disorder but exhibiting recurrent suicidal gestures, threats, or self-mutilating behaviors should also be excluded
  • Participant has a current clinical diagnosis of autism, dementia, or intellectual disability
  • Participant has a current or prior DSM-5 diagnosis of a psychotic disorder, or MDD with psychotic features
  • Participant meets the DSM-5 severity criteria for moderate or severe substance or alcohol use disorder, (except for nicotine or caffeine), within the 12 months before Screening. A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 4-methylenedioxy-methamphetamine (MDMA) hallucinogen-related use disorder is exclusionary
  • Participant has a history or current signs and symptoms of liver or renal insufficiency, cardiac (including unstable coronary artery disease and congestive heart failure, tachyarrhythmias and recent myocardial infarction) or vascular, pulmonary, gastrointestinal, endocrine (including uncontrolled hyperthyroidism), neurologic (including current or past history of seizures except uncomplicated childhood febrile seizures with no sequelae), hematologic, rheumatologic, or metabolic (including severe dehydration/ hypovolemia) disease
  • Participant has known allergies, , intolerance or to esketamine or ketamine or its
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
230 participants (actual)

Study arms

  • Experimental
    Esketamine + Standard of care

    Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.

    Drug: Esketamine · Other: Standard of Care

  • Placebo comparator
    Placebo + Standard of care

    Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.

    Drug: Placebo · Other: Standard of Care

Interventions

  • Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).

  • DrugPlacebo

    Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).

  • OtherStandard of Care

    The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase

    MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)

  2. Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase

    Clinical global impression-severity of suicidality-revised (CGI-SS-R) scale is revised version of the clinical global impression severity scale (CGI-S),a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)

Secondary outcomes

  1. Number of Participants With Remission of Major Depressive Disorder (MADRS Total Score Less Than or Equal to [<=] 12): DB Treatment Phase

    MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

    Time frame: Days 1 (4 hours [h] postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)

  2. Change From Baseline in MADRS Total Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

    MADRS is a clinician-rated scale designed to be used in participants with MDD to measure depression severity and detect changes due to antidepressant treatment. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The instrument consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)

  3. Change From Baseline in CGI-SS-R Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

    CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. A higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25

  4. Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1): DB Treatment Phase

    CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. A participant was considered to have achieved resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). Participants who did not met such criterion or discontinued prior to the time point for any reason were not considered to have resolution of suicidality.

    Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25

  5. Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

    The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25

  6. Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 in DB Treatment Phase

    BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.

    Time frame: Baseline, Days 8 and 25

  7. Change From Baseline in European Quality of Life Group, 5-Dimension, 5-Level (EQ-5D-5L) Sum Score at Days 2, 11 and 25 of the DB Treatment Phase

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (no problem, slight, moderate, severe and extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst imaginable health)-100 (best imaginable health). Sum score ranges from 0 -100. Sum score=(sum of the scores from the 5 dimensions minus 5)\*5. Higher score indicates worse health state. Negative change in score indicates improvement.

    Time frame: Baseline, Days 2, 11 and 25

  8. Change From Baseline in European Quality of Life Group, Visual Analogue Scale (EQ-VAS) Score at Days 2, 11 and 25 of the DB Treatment Phase

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Positive change in score indicates improvement.

    Time frame: Baseline, Days 2, 11 and 25

  9. Change From Baseline in EQ-5D-5L Health Status Index at Days 2, 11 and 25 of the DB Treatment Phase

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). Positive change in score indicates improvement.

    Time frame: Baseline, Days 2, 11 and 25

  10. Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 of the DB Treatment Phase

    The QLDS is a disease-specific patient-reported outcome designed to assess health-related quality of life in patients with MDD, it captures the impact of depression and its treatment from the participant's perspective. The instrument has a recall period of "at the moment" and contains 34 items with "true"/"not true" response options. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.

    Time frame: Baseline, Days 2, 11 and 25

  11. Treatment Satisfaction Questionnaire for Medication (TSQM-9) Domain Score at Days 15 and 25: DB Treatment Phase

    The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = \[(item 1 + item 2 + item 3) - 3\]/18\*100, (ii) Convenience = \[(item 4 + item 5 + item 6) - 3\]/18\*100 and (iii) Global satisfaction = \[(item 7 + item 8 + item 9) - 3\]/14\*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction.

    Time frame: Days 15 and 25

  12. Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Participant-Reported Frequency of Suicidal Thinking) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

    SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time).

    Time frame: Baseline, Days 1 (4h postdose), 2, 4, 8, 11, 15, 18, 22 and 25

  13. Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

    SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline, Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25

  14. Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent.

    Time frame: Up to Day 25

  15. Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase

    Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin (low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine (High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0\*1012/L,high=6.4\*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5\*109/L,high=15.5\*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100\*109/L,high=600\*109/L\]; Potassium(low=3.0mmol/L,high=5.8 mmol/L\]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH).

    Time frame: Up to Day 25

  16. Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase

    Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed.

    Time frame: At Day 25

  17. Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase

    Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\] , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec) were reported.

    Time frame: Up to Day 25

  18. Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase

    Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (\<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to \>= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported.

    Time frame: Up to Day 25

  19. Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase

    Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm \[abnormally low = a decrease from baseline of \>= 15 to a value \<= 50; abnormally high = an increase from baseline of \>=15 to a value \>=100\] , systolic blood pressure \[SBP\] in mmHg \[abnormally low = a decrease from baseline of \>= 20 to a value \<= 90; abnormally high = an increase from baseline of \>= 20 to a value \>= 180\], and diastolic blood pressure \[DBP\] in mmHg \[abnormally low= a decrease from baseline of \>=15 to a value \<= 50; abnormally high = an increase from baseline of \>= 15 to a value \>= 105) were reported.

    Time frame: Up to Day 25

  20. Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase

    MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation.

    Time frame: Up to Day 25

  21. Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase

    The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of \> 0) was reported.

    Time frame: Days 1, 4, 8, 11, 15, 18, 22 and 25

07

Results

Posted Sep 25, 2020
Limitations and caveats
Esketamine's known characteristic effects such as dissociative symptoms, sedation, and elevation of blood pressure may have impact on blinding, to minimize this bias, protocol specified that different raters perform efficacy and safety assessments.

Participant flow

Participant flow — Overall Study
MilestonePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Started115115
Treated113114
Completed8581
Not completed3034
Withdrew: Lost to follow-up32
Withdrew: Withdrawal by subject25
Withdrew: Discontinued db, not entered fu phase2125
Withdrew: Other32
Withdrew: Adverse event10

Outcome measures

PrimaryChange From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase

MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Reported as:
Mean · units on a scale
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase-12.4 ± 10.43-15.7 ± 11.56
Statistical analysis
  • Placebo + Standard of Care (SOC) vs Esketamine 84 mg + SOC · ANCOVA · p = 0.006 · Difference of least square means: -3.9 · 95% CI -6.60 to -1.11
PrimaryChange From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase

Clinical global impression-severity of suicidality-revised (CGI-SS-R) scale is revised version of the clinical global impression severity scale (CGI-S),a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Reported as:
Median · units on a scale
Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase-1.0 (-5 to 2)-1.0 (-6 to 2)
SecondaryNumber of Participants With Remission of Major Depressive Disorder (MADRS Total Score Less Than or Equal to [<=] 12): DB Treatment Phase

MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

Time frame:
Days 1 (4 hours [h] postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
Reported as:
Count of participants · Participants
Number of Participants With Remission of Major Depressive Disorder (MADRS Total Score Less Than or Equal to [<=] 12): DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Day 1: 4 hours post dose412
Day 21225
Day 42026
Day 82328
Day 112632
Day 152936
Day 183229
Day 223742
Day 25: Predose3149
Day 25: 4 hours postdose4254
SecondaryChange From Baseline in MADRS Total Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

MADRS is a clinician-rated scale designed to be used in participants with MDD to measure depression severity and detect changes due to antidepressant treatment. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The instrument consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 1: 4 hours postdose-8.2 ± 7.62-12.2 ± 9.87
Change at Day 2-12.4 ± 10.51-16.0 ± 11.52
Change at Day 4-15.7 ± 11.50-17.7 ± 11.94
Change at Day 8-17.4 ± 11.29-20.1 ± 11.47
Change at Day 11-19.5 ± 11.60-21.3 ± 11.45
Change at Day 15-20.0 ± 12.54-23.4 ± 10.62
Change at Day 18-21.4 ± 12.90-23.1 ± 11.39
Change at Day 22-22.0 ± 12.12-24.5 ± 11.57
Change at Day 25: Predose-22.5 ± 12.23-26.2 ± 11.09
Change at Day 25: 4 hours postdose-26.4 ± 11.18-28.7 ± 10.88
SecondaryChange From Baseline in CGI-SS-R Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. A higher score indicates a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in CGI-SS-R Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 1: 4 hours postdose-1.0 (-4 to 1)-1.0 (-6 to 1)
Change at Day 2-1.0 (-5 to 2)-1.0 (-6 to 2)
Change at Day 4-2.0 (-5 to 2)-2.0 (-6 to 1)
Change at Day 8-2.0 (-5 to 2)-2.0 (-5 to 2)
Change at Day 11-2.0 (-6 to 2)-3.0 (-6 to 1)
Change at Day 15-3.0 (-5 to 2)-3.0 (-6 to 0)
Change at Day 18-3.0 (-6 to 1)-3.0 (-5 to 0)
Change at Day 22-3.0 (-5 to 3)-3.0 (-5 to 0)
Change at Day 25-3.0 (-6 to 4)-3.0 (-6 to 0)
SecondaryNumber of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1): DB Treatment Phase

CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. A participant was considered to have achieved resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). Participants who did not met such criterion or discontinued prior to the time point for any reason were not considered to have resolution of suicidality.

Time frame:
Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1): DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Day 1: 4 hours postdose2038
Day 23536
Day 45152
Day 85453
Day 115862
Day 155865
Day 185962
Day 226568
Day 256669
SecondaryChange From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 1: 4 hours postdose0.0 (-4 to 2)-1.0 (-6 to 3)
Change at Day 2-1.0 (-4 to 2)-1.0 (-6 to 2)
Change at Day 4-2.0 (-5 to 2)-2.0 (-6 to 1)
Change at Day 8-2.0 (-5 to 2)-2.0 (-5 to 2)
Change at Day 11-2.0 (-5 to 1)-2.0 (-6 to 2)
Change at Day 15-3.0 (-5 to 2)-2.0 (-6 to 1)
Change at Day 18-3.0 (-5 to 2)-3.0 (-5 to 1)
Change at Day 22-3.0 (-5 to 2)-3.0 (-5 to 0)
Change at Day 25-3.0 (-5 to 2)-3.0 (-6 to 1)
SecondaryChange From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 in DB Treatment Phase

BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.

Time frame:
Baseline, Days 8 and 25
Reported as:
Mean · units on a scale
Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 in DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 8-6.3 ± 6.31-6.1 ± 6.17
Change at Day 25-7.0 ± 6.47-8.0 ± 6.31
SecondaryChange From Baseline in European Quality of Life Group, 5-Dimension, 5-Level (EQ-5D-5L) Sum Score at Days 2, 11 and 25 of the DB Treatment Phase

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (no problem, slight, moderate, severe and extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst imaginable health)-100 (best imaginable health). Sum score ranges from 0 -100. Sum score=(sum of the scores from the 5 dimensions minus 5)\*5. Higher score indicates worse health state. Negative change in score indicates improvement.

Time frame:
Baseline, Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life Group, 5-Dimension, 5-Level (EQ-5D-5L) Sum Score at Days 2, 11 and 25 of the DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 2-9.0 ± 12.30-11.8 ± 14.45
Change at Day 11-15.1 ± 16.32-15.0 ± 15.51
Change at Day 25-15.3 ± 15.78-18.8 ± 16.96
SecondaryChange From Baseline in European Quality of Life Group, Visual Analogue Scale (EQ-VAS) Score at Days 2, 11 and 25 of the DB Treatment Phase

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Positive change in score indicates improvement.

Time frame:
Baseline, Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life Group, Visual Analogue Scale (EQ-VAS) Score at Days 2, 11 and 25 of the DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 29.7 ± 15.5713.4 ± 22.58
Change at Day 1117.6 ± 24.8721.4 ± 26.95
Change at Day 2518.6 ± 25.3927.0 ± 27.54
SecondaryChange From Baseline in EQ-5D-5L Health Status Index at Days 2, 11 and 25 of the DB Treatment Phase

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). Positive change in score indicates improvement.

Time frame:
Baseline, Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D-5L Health Status Index at Days 2, 11 and 25 of the DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 20.129 ± 0.17320.160 ± 0.1872
Change at Day 110.194 ± 0.21730.202 ± 0.2051
Change at Day 250.194 ± 0.21490.235 ± 0.2228
SecondaryChange From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 of the DB Treatment Phase

The QLDS is a disease-specific patient-reported outcome designed to assess health-related quality of life in patients with MDD, it captures the impact of depression and its treatment from the participant's perspective. The instrument has a recall period of "at the moment" and contains 34 items with "true"/"not true" response options. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.

Time frame:
Baseline, Days 2, 11 and 25
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 of the DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 2-2.5 ± 3.93-3.5 ± 4.93
Change at Day 11-5.2 ± 5.55-5.1 ± 6.16
Change at Day 25-5.5 ± 6.03-6.3 ± 6.26
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM-9) Domain Score at Days 15 and 25: DB Treatment Phase

The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = \[(item 1 + item 2 + item 3) - 3\]/18\*100, (ii) Convenience = \[(item 4 + item 5 + item 6) - 3\]/18\*100 and (iii) Global satisfaction = \[(item 7 + item 8 + item 9) - 3\]/14\*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction.

Time frame:
Days 15 and 25
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM-9) Domain Score at Days 15 and 25: DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Effectiveness: Day 1555.3 ± 27.9363.5 ± 26.05
Effectiveness: Day 2554.8 ± 28.8468.8 ± 25.41
Convenience: Day 1577.2 ± 16.7371.3 ± 18.38
Convenience: Day 2576.9 ± 17.9277.0 ± 18.66
Global Satisfaction: Day 1559.7 ± 27.1263.6 ± 27.69
Global Satisfaction: Day 2556.8 ± 28.3171.5 ± 24.85
SecondaryChange From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Participant-Reported Frequency of Suicidal Thinking) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time).

Time frame:
Baseline, Days 1 (4h postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Participant-Reported Frequency of Suicidal Thinking) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 1: 4 hours postdose-1.0 (-3 to 1)-1.0 (-4 to 2)
Change at Day 2-1.0 (-4 to 1)-1.0 (-4 to 2)
Change at Day 4-1.0 (-4 to 1)-1.0 (-4 to 4)
Change at Day 8-2.0 (-4 to 1)-2.0 (-4 to 4)
Change at Day 11-2.0 (-4 to 1)-2.0 (-4 to 4)
Change at Day 15-2.0 (-4 to 0)-2.0 (-4 to 1)
Change at Day 18-2.0 (-4 to 2)-2.0 (-4 to 3)
Change at Day 22-2.0 (-4 to 1)-2.0 (-4 to 3)
Change at Day 25-2.0 (-4 to 1)-2.0 (-4 to 4)
SecondaryChange From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase

SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline, Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Median · units on a scale
Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
units on a scalePlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Change at Day 1: 4 hours postdose-1.0 (-4 to 2)-1.0 (-5 to 1)
Change at Day 2-1.0 (-5 to 1)-1.0 (-5 to 1)
Change at Day 4-2.0 (-5 to 1)-2.0 (-5 to 1)
Change at Day 8-2.0 (-4 to 1)-2.0 (-5 to 1)
Change at Day 11-2.0 (-5 to 2)-2.0 (-5 to 1)
Change at Day 15-2.0 (-5 to 2)-3.0 (-5 to 0)
Change at Day 18-2.0 (-5 to 1)-3.0 (-5 to 1)
Change at Day 22-2.0 (-5 to 2)-3.0 (-5 to 2)
Change at Day 25-2.0 (-5 to 4)-3.0 (-5 to 2)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase87104
SecondaryNumber of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase

Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin (low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine (High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0\*1012/L,high=6.4\*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5\*109/L,high=15.5\*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100\*109/L,high=600\*109/L\]; Potassium(low=3.0mmol/L,high=5.8 mmol/L\]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH).

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
ALT: ALT>3*ULN22
ALT: Abnormal High00
Albumin: Abnormal High00
Albumin: Abnormal Low00
Alkaline phosphatase (ALP): Abnormal High00
AST: AST>3*ULN00
AST: Abnormal High00
Bicarbonate: Abnormal High00
Bicarbonate: Abnormal Low00
Bilirubin: Abnormal High00
Calcium: Abnormal High00
Calcium: Abnormal Low00
Chloride: Abnormal High00
Chloride: Abnormal Low00
Creatine Kinase (CK): Abnormal High00
Creatinine: Abnormal High00
GGT: Abnormal High31
Glucose: Abnormal High01
Glucose: Abnormal Low00
ALT>3*ULN or AST>3*ULN and BILI>2*ULN00
Lactate Dehydrogenase (LD): Abnormal High00
Phosphate: Abnormal High00
Phosphate: Abnormal Low01
Potassium: Abnormal High10
Potassium: Abnormal Low00
Protein: Abnormal Low00
Sodium: Abnormal High00
Sodium: Abnormal Low00
Urate: Abnormal High00
Urate: Abnormal Low00
Basophils: Abnormal High00
Eosinophils: Abnormal High00
Erythrocytes: Abnormal High01
Erythrocytes: Abnormal Low00
Hematocrit: Abnormal High02
Hematocrit: Abnormal Low00
Hemoglobin (Hb): Abnormal High01
Hemoglobin: Abnormal Low00
Leukocytes: Abnormal High10
Leukocytes: Abnormal Low00
Lymphocytes: Abnormal High00
Lymphocytes: Abnormal Low21
Monocytes: Abnormal High00
Neutrophils: Abnormal High00
Neutrophils: Abnormal Low01
Platelets: Abnormal High00
Platelets: Abnormal Low01
Urine pH: Abnormal High00
SecondaryNumber of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase

Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed.

Time frame:
At Day 25
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Epistaxis: Mild11
Epistaxis: Moderate00
Epistaxis: Severe00
Nasal Crusts: Mild01
Nasal Crusts: Moderate00
Nasal Crusts: Severe00
Nasal Discharge: Mild01
Nasal Discharge: Moderate00
Nasal Discharge: Severe00
Nasal Erythema: Mild14
Nasal Erythema: Moderate10
Nasal Erythema: Severe00
SecondaryNumber of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase

Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\] , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec) were reported.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Heart Rate <= 50 bpm92
Heart Rate >= 100 bpm32
PR Duration >= 210 msec22
QRS Duration <= 50 msec00
QRS Duration >= 120 msec10
QT Duration <= 200 msec00
QT Duration >= 500 msec00
SecondaryNumber of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase

Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (\<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to \>= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase23
SecondaryNumber of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase

Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm \[abnormally low = a decrease from baseline of \>= 15 to a value \<= 50; abnormally high = an increase from baseline of \>=15 to a value \>=100\] , systolic blood pressure \[SBP\] in mmHg \[abnormally low = a decrease from baseline of \>= 20 to a value \<= 90; abnormally high = an increase from baseline of \>= 20 to a value \>= 180\], and diastolic blood pressure \[DBP\] in mmHg \[abnormally low= a decrease from baseline of \>=15 to a value \<= 50; abnormally high = an increase from baseline of \>= 15 to a value \>= 105) were reported.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Pulse rate (bpm): Decrease of >=15 to <=5021
Pulse rate (bpm): Increase of >=15 to >=1001112
SBP: Decrease of >=20 to <=9052
SBP (mmHg): Increase of >=20 to >=18023
DBP (mmHg): Decrease of >=15 to <=5044
DBP (mmHg): Increase of >=15 to >=10536
SecondaryNumber of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase

MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation.

Time frame:
Up to Day 25
Reported as:
Count of participants · Participants
Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Score <=2: Yes04
Score <=3: Yes321
Score <=4: Yes2065
SecondaryNumber of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase

The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of \> 0) was reported.

Time frame:
Days 1, 4, 8, 11, 15, 18, 22 and 25
Reported as:
Count of participants · Participants
Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase
ParticipantsPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Day 128106
Day 42186
Day 81675
Day 11868
Day 151168
Day 18853
Day 22758
Day 25456

Adverse events

Collected over Up to Day 25. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Standard of Care (SOC)0/113 (0%)6/113 (5.3%)74/113 (65.5%)
Esketamine 84 mg + SOC0/114 (0%)5/114 (4.4%)98/114 (86%)
Most frequent serious events
Most frequent serious events
EventPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
Suicide AttemptPsychiatric disorders3/1133/114
Suicidal IdeationPsychiatric disorders2/1131/114
ArrhythmiaCardiac disorders1/1130/114
Pericardial EffusionCardiac disorders1/1130/114
DepressionPsychiatric disorders1/1130/114
PneumothoraxRespiratory, thoracic and mediastinal disorders1/1130/114
Depersonalisation/Derealisation DisorderPsychiatric disorders0/1131/114
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlacebo + Standard of Care (SOC)Esketamine 84 mg + SOC
DizzinessNervous system disorders21/11347/114
DissociationPsychiatric disorders9/11344/114
NauseaGastrointestinal disorders16/11338/114
DysgeusiaNervous system disorders18/11329/114
HeadacheNervous system disorders26/11325/114
SomnolenceNervous system disorders12/11326/114
ParaesthesiaNervous system disorders7/11323/114
VomitingGastrointestinal disorders5/11318/114
Vision BlurredEye disorders6/11317/114
AnxietyPsychiatric disorders7/11317/114

Baseline characteristics

Full efficacy analysis set included all randomized participants who received at least 1 dose of intranasal study agent during DB treatment phase and had both baseline and post baseline evaluation for Montgomery-Asberg Depression Rating Scale (MADRS) total score or Clinical Global Impression - Severity of Suicidality - Revised (CGI-SS-R).

Age, Continuous
Age, Continuous(years)Placebo + Standard of Care (SOC)Esketamine 84 mg + SOCTotal
Mean41.4 ± 13.4340.2 ± 12.7340.8 ± 13.07
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Standard of Care (SOC)Esketamine 84 mg + SOCTotal
Female6769136
Male464591
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + Standard of Care (SOC)Esketamine 84 mg + SOCTotal
American Indian or Alaska Native101
Asian213
Native Hawaiian or Other Pacific Islander101
Black or African American8715
White8792179
More than one race6814
Unknown or Not Reported8614
Region of Enrollment
Region of Enrollment(Participants)Placebo + Standard of Care (SOC)Esketamine 84 mg + SOCTotal
ARGENTINA9716
AUSTRIA549
BELGIUM213
BRAZIL181836
CANADA101
CZECH REPUBLIC213
FRANCE91524
LITHUANIA123
POLAND151833
SPAIN5510
TURKEY101323
UNITED STATES363066
08

Study locations

61 sites
  • University of California San Diego/Psychiatry
    San Diego, California 92103-8229, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123, United States
  • University of Conneticut School of Medicine
    Farmington, Connecticut 06030, United States
  • University of Miami Health System
    Miami, Florida 33136, United States
  • Innovative Clinical Research Inc
    North Miami, Florida 33161, United States
  • University of South Florida
    Tampa, Florida 33613, United States
  • Atlanta Behavioral Research, LLC
    Atlanta, Georgia 30338, United States
  • Memorial Medical Center
    Springfield, Illinois 62702, United States
  • Neuroscience Research Institute
    Winfield, Illinois 60190, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70629, United States
  • John Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • The Zucker Hillside Hospital
    Glen Oaks, New York 11004, United States
  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • East Tennessee State University
    Johnson City, Tennessee 37604, United States
  • University of Wisconsin Medical Center
    Madison, Wisconsin 53705, United States
  • Clínica Privada Banfield S.A
    Banfield, B1828CKR, Argentina
  • Hospital Fleni
    Ciudad de Buenos Aires, C1428AQK, Argentina
  • Sanatorio Prof. Leon S. Morra
    Cordoba, X5009BIN, Argentina
  • Clinica Privada de Salud Mental Santa Teresa de Ávila
    La Plata, B1904ADM, Argentina
  • Medical University Vienna MUV
    Vienna, 1090, Austria
  • Klinikum Wels Grieskirchen
    Wels, 4600, Austria
  • AZ Sint Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • ARIADNE
    Lede, 9340, Belgium
  • Universidade Federal De Minas Gerais - Hospital das Clínicas
    Belo Horizonte, 30130-100, Brazil
  • Universidade Federal Do Ceara
    Fortaleza, 60430-370, Brazil
  • Instituto Bairral de Psiquiatria
    Itapira, 13970-905, Brazil
  • Hospital Universitario Professor Edgar Santos
    Salvador, 40110-060, Brazil
  • CEMEC - Centro Multidisciplinar de Estudos Clínicos
    Santo Andre, 09190-510, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina Da USP
    São Paulo, 05403-903, Brazil
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • Institut universitaire en sante mentale de Montreal
    Montréal, Quebec H1N 3M5, Canada
  • Fakultni nemocnice Brno
    Brno, 62500, Czechia
  • Nemocnice s pol. Havirov, p.o.
    Havirov, 73601, Czechia
  • Narodni ustav dusevniho zdravi
    Klecany, 25067, Czechia
  • Vseobecna Fakultní Nemocnice
    Praha, 12000, Czechia
  • Ústrední vojenské nemocnice Praha
    Praha, 16902, Czechia
  • Hôpital de Bohars
    Bohars, 29820, France
  • CHRU Montpellier Hopital Lapeyronie
    Montpellier, 34090, France
  • CHU Caremeau
    Nimes, 30029, France
  • Hopital Sainte Anne
    Paris, 75014, France
  • CHU Saint Etienne Hopital Nord
    Saint-Priest en Jarez, 42270, France
  • CHU Toulouse
    Toulouse, 31059, France
  • Republic Kaunas Hospital
    Kaunas County, Lithuania
  • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
    Kaunas, LT-50009, Lithuania
  • Vilnius Mental Health Center
    Vilnius, 10309, Lithuania
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80 124, Poland
  • Szpital Specjalistyczny im H Klimontowicza Oddzial Psychiatryczny
    Gorlice, 38-300, Poland
  • SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych
    Lodz, 92-216, Poland
  • Klinika Psychiatryczna WUM Mazowieckie Specjalistyczne Centrum Zdrowia im prof Jana Mazurkiewicza
    Pruszkow, 05 802, Poland
  • Hosp Univ Vall D Hebron
    Barcelona, 08035, Spain
  • Inst. Internac. Neurociencias Aplicadas
    Barcelona, 8006, Spain
  • Hosp. Univ. de Basurto
    Bilbao, 48013, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Bursa Sevket Yilmaz Research and Training Hospital
    Bursa, 16240, Turkey
  • Uludag University Medical Faculty
    Bursa, 16285, Turkey
  • Sisli Etfal Research Training Hospital
    Istanbul, 34360, Turkey
  • Samsun Psychiatric Hospital
    Samsun, 55070, Turkey
09

References and documents

Publications

  • Rozjabek H, Li N, Hartmann H, Fu DJ, Canuso C, Jamieson C. Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray. J Patient Rep Outcomes. 2022 Jul 10;6(1):74. doi: 10.1186/s41687-022-00453-y. PubMed 35816217 ↗
  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗
  • Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2021 Jan 20;24(1):22-31. doi: 10.1093/ijnp/pyaa068. PubMed 32861217 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Apr 2019, 21 months.

Results were first posted in Sep 2020, 1 year 5 months after primary completion. A results delay was requested in Apr 2020.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 21 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2017
First posted
Mar 31, 2017
StartActual
Jun 15, 2017
Primary completionActual
Apr 11, 2019
CompletionActual
Apr 11, 2019
Results delay requested
Apr 7, 2020
Results first posted
Sep 25, 2020
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03097133
Responsible party
Sponsor
First posted
Mar 31, 2017
Start date
Jun 15, 2017
Primary completion
Apr 11, 2019
Completion
Apr 11, 2019
Results posted
Sep 25, 2020
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion